Skip to content

Clinical trials

Observational Aortic Valve Stenosis trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Aortic Valve Stenosis Phase: Observational Country / region: Italy Clear all

69 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20103
20112
20122
20136
20145
20153
20163
20176
20185
20195
20204
20215
20222
20237
20247
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed33
Recruiting15
Unknown status11
Active, not recruiting4
Enrolling by invitation2
Terminated2
Withdrawn1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institut für Pharmakologie und Präventive Medizin7
Edwards Lifesciences6
Medtronic Cardiac Rhythm and Heart Failure5
Boston Scientific Corporation3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3
IRCCS Policlinico S. Donato3
Niguarda Hospital3
University Hospital of Ferrara3
Abbott Medical Devices2
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Aortic Valve Stenosis69
Aortic Valve Insufficiency7
Heart Valve Diseases5
Aortic Valve Disease4
Cardiovascular Diseases3
Coronary Artery Disease2
Heart Diseases2
Amyloid Neuropathies, Familial1
Amyloidosis1
Aneurysm, Ascending Aorta1

Trials

Showing 1 to 25 of 69. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.